CSL Limited, a biotechnology company that produce many of its biological products from plasma, is diversifying its portfolio and its drug pipeline through its largest ever acquisition: the purchase of ...

MELBOURNE, Australia--Australian biotechnology firm CSL Ltd. (CSL.AU) has struck a deal to buy control of a plasma-derived therapies manufacturer in China from Humanwell Healthcare Group Co.

CSL is one of three tier one plasma therapy companies who benefit from an oligopoly in this highly consolidated market. All the players are vertically integrated as plasma sourcing is the most ...

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring ...

ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ...

Dave Ross - Senior Vice President and General Manager, CSL Seqirus Hervé Gisserot - Senior Vice President and General Manager, CSL Vifor Thank you for standing by and welcome to the CSL Limited Half ...

Ladies and gentlemen, good morning and welcome to CSL's Full-Year Results Call for Fiscal 2023. It's Mark Dehring speaking, and joining me online is Paul McKenzie, CSL's Chief Executive Officer; Joy ...

SYDNEY – Blood products and vaccine company CSL Ltd. (CSL.AU) said Wednesday annual net profit rose nearly 8%, reflecting growth in sales of immunoglobulin and specialty products. CSL, which ...

CSL is well ahead of Grifols in evolving its business to recombinant products and Grifols is not pursuing gene therapy at present. CSL is also the only player with a direct presence in China which is ...

Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global specialty pharmaceutical company with leadership in iron deficiency, ...